Royal Bank of Canada trimmed its stake in PAREXEL International Corporation (NASDAQ:PRXL) by 5.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 783,992 shares of the medical research company’s stock after selling 44,601 shares during the quarter. Royal Bank of Canada owned about 1.54% of PAREXEL International Corporation worth $68,136,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. First Trust Advisors LP raised its holdings in shares of PAREXEL International Corporation by 216.7% during the first quarter. First Trust Advisors LP now owns 29,536 shares of the medical research company’s stock valued at $1,864,000 after purchasing an additional 20,210 shares during the period. Karp Capital Management Corp bought a new position in shares of PAREXEL International Corporation during the 1st quarter worth about $671,000. Raymond James Financial Services Advisors Inc. boosted its position in shares of PAREXEL International Corporation by 54.3% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 4,826 shares of the medical research company’s stock worth $305,000 after purchasing an additional 1,699 shares in the last quarter. Pacer Advisors Inc. grew its stake in shares of PAREXEL International Corporation by 12.6% in the 1st quarter. Pacer Advisors Inc. now owns 5,405 shares of the medical research company’s stock valued at $341,000 after buying an additional 605 shares during the period. Finally, Nordea Investment Management AB increased its position in PAREXEL International Corporation by 18.3% in the 1st quarter. Nordea Investment Management AB now owns 23,098 shares of the medical research company’s stock valued at $1,458,000 after buying an additional 3,568 shares in the last quarter. Institutional investors and hedge funds own 87.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Royal Bank of Canada Trims Holdings in PAREXEL International Corporation (PRXL)” was posted by Marea Informative and is owned by of Marea Informative. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at http://www.mareainformativa.com/royal-bank-of-canada-trims-holdings-in-parexel-international-corporation-prxl/115165/.

A number of equities research analysts have commented on the company. Zacks Investment Research cut PAREXEL International Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Credit Suisse Group reaffirmed a “neutral” rating and set a $83.00 target price (up from $65.00) on shares of PAREXEL International Corporation in a research report on Tuesday, June 6th. BidaskClub cut PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Raymond James Financial, Inc. raised shares of PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $88.10 price target on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company. PAREXEL International Corporation presently has a consensus rating of “Hold” and an average target price of $75.92.

PAREXEL International Corporation (NASDAQ PRXL) traded down 0.02% during trading on Wednesday, hitting $88.08. 7,021,106 shares of the company’s stock traded hands. PAREXEL International Corporation has a 12 month low of $51.16 and a 12 month high of $88.10. The stock has a market cap of $4.50 billion, a P/E ratio of 42.76 and a beta of 0.77. The company’s 50 day moving average is $87.74 and its 200-day moving average is $78.14.

PAREXEL International Corporation (NASDAQ:PRXL) last posted its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.08. The firm had revenue of $557.20 million during the quarter, compared to analyst estimates of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same quarter in the previous year, the firm earned $0.94 EPS. On average, analysts predict that PAREXEL International Corporation will post $3.95 earnings per share for the current year.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.